CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...